Octaplaslg (Human Plasma Protein)

Octaplaslg is a plasma‑derived protein supplement that acts on the coagulation cascade to manage bleeding and support clot formation.

• Congenital coagulation factor deficiency: Provides missing clotting factors to reduce bleeding episodes.
• Massive transfusion protocols: Restores hemostatic balance during extensive blood loss.
• Liver transplantation: Supplies necessary plasma proteins to maintain coagulation during surgery.
• Cardiac surgery with cardiopulmonary bypass: Helps control intra‑operative bleeding.
• Trauma‑induced coagulopathy: Contributes to rapid correction of coagulation deficits.
• Hemophilia‑related surgical procedures: Offers supplemental clotting factors for peri‑operative management.

• Octaplaslg contains a pooled, solvent‑detergent‑treated human plasma protein concentrate that provides a broad spectrum of functional clotting factors (including fibrinogen, prothrombin, and factors V, VII, IX, X, XI, and XII). By replenishing these factors, it restores the physiological cascade of thrombin generation and fibrin clot formation, thereby supporting normal hemostasis in patients with deficient or consumed plasma proteins.

Adverse reactions to Octaplaslg are generally related to its plasma origin and the infusion process.

Common Side Effects

• Fever: Mild temperature elevation during or after infusion.
• Chills: Transient shivering episodes.
• Headache: Mild to moderate discomfort.
• Nausea: Temporary feeling of queasiness.
• Hypotension: Slight drop in blood pressure post‑infusion.
• Rash: Localized skin redness.

Serious or Rare Side Effects

• Anaphylaxis: Severe allergic reaction requiring immediate medical intervention.
• Transfusion‑related acute lung injury (TRALI): Acute respiratory distress following infusion.
• Volume overload: Pulmonary edema due to excess fluid administration.
• Hemolysis: Destruction of red blood cells.
• Sepsis: Infection risk from contaminated product.
• Thromboembolic events: Formation of clots in vessels.

Octaplaslg should be administered under close clinical supervision with attention to patient history and infusion parameters.

• Verify patient identity and indication: Confirm appropriate clinical use before infusion.
• Assess bleeding risk: Evaluate coagulation profile and recent anticoagulant use.
• Monitor vital signs: Observe blood pressure, heart rate, and temperature during infusion.
• Use aseptic technique: Prevent contamination of the product.
• Adjust infusion rate: Slow the rate if reactions occur.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octaplaslg may interact with other agents that affect hemostasis or immune response.

Major Interactions (Avoid)

• Anticoagulants (e.g., heparin, warfarin): May exacerbate bleeding risk when combined.
• High‑dose fibrinolytics: Can increase risk of uncontrolled hemorrhage.

Moderate Interactions (Monitor Closely)

• Immunoglobulin preparations: May heighten risk of allergic reactions.
• Corticinal Corticosteroids: Potential for altered immune response.
• ACE‑Inhibitors: May contribute to hypotensive episodes during infusion.
• Diuretics: Can affect fluid balance and increase risk of volume overload.
• NSAIDs: May potentiate bleeding tendencies.